Reportlinker Adds The Future of the Biologicals Market: Market overview, innovations and company profiles

NEW YORK, April 6 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Future of the Biologicals Market: Market overview, innovations and company profiles

http://www.reportlinker.com/p0186711/The-Future-of-the-Biologicals-Market-Market-overview-innovations-and-company-profiles.html

Biopharmaceutical products are the key to the future of the pharmaceutical market. Even before the market stagnation seen in 2009 due to the recession, conventional pharmaceuticals were facing drastic consequences from the loss of patent cover for many blockbusters, and the continued failure of the R&D departments in big pharma to produce replacement candidates.

Although the conventional, small-molecule segment of the market will continue to hold a larger share, their growth is expected to be in low single figures, while biopharma products are forecast to grow at rates up to 10% per annum.

This report analyses the three main components of the biopharma market – monoclonal antibodies, therapeutic proteins and vaccines – to show why these groups have such a positive future. It provides the most up-to-date discussion of the whole biopharma market and explores new clinical indications beyond those already targeted.

Key features of this report

-- Monoclonal antibodies will build on recent market growth as new product candidates come onstream and new indications are confirmed, extending the usefulness of Mabs beyond cancers and autoimmune disease to CNS conditions, infections and others.

-- The Therapeutic Proteins class will continue to be dominated by hematopoietic growth factor products for cancer-related neutropenia and anemia.

-- Cytokines are another important contributor to the Therapeutic Proteins sector, and new uses for them are under investigation, including cancers, benign prostatic hyperplasia, gout, wound healing and inflammatory diseases such as Crohn's.

-- Buoyancy in the Vaccines sector is driven by anxiety over bioterrorism, the ongoing risk of a global influenza pandemic and new targets for prevention.

-- The prospect of therapeutic vaccines, especially against cancers, is another major driver in the vaccines market.

Scope of this report

-- The report gives a realistic picture of the strengths and limitations of the biopharma marketplace, indicating those product groups whose strengths are set to last while avoiding over-optimistic forecasts of growth over the next five years.

-- In terms of R&D activity, the report aims to give the reader a perspective on the important research avenues now being pursued, while updating the reader with an overview of recent R&D developments .

-- By covering all the three major segments of the biopharma market, the report gives a better perspective of the contribution of biopharma to the management of some major diseases than would be gleaned from studying only a single product type.

Key Market Issues

v Monoclonal antibodies are forecast to grow at a CAGR approaching 10% over the next five years, driven largely by good results in the clinic

-- Cancers and immune-related inflammatory diseases will continue to be leading issues of Mabs during the five-year forecast period

-- New indications offer the prospect of major market growth for cytokines; these include cancers and inflammatory diseases

-- Other therapeutic proteins such as growth factors, coagulation factors and erythropoietins, have limited opportunities for growth through excpanding indications, and depend instead on product improvements

Key findings from this report

-- In terms of market size, therapeutic proteins are the leaders, but monoclonal antibodies (MAbs) are the fastest growing sector

-- Cancer still ranks high among targets for new MAb development, along with treatments for inflammation/immune related diseases including rheumatoid arthritis and multiple sclerosis

-- Cytokines in advanced development include treatments for cancers, benign prostatic hyperplasia, gout and inflammatory conditions such as Crohn's disease.

• By the end of 2009 there were 29 monoclonal antibodies approved and marketed for therapeutic use. This product class is now approaching maturity.

-- Therapeutic protein products which have been success stories include insulin, erythropoietin, growth hormone, the interferons, and the fusion protein Enbrel (etanercept)

Key questions answered

-- What indications will be the main market drivers for Mabs during the next five years?

-- What are the most important market trends in the vaccines market?

-- Will the biopharma market perform any better than the overall pharma market during the next five years, and why?

-- Which segments of the therapeutic protein market are likely to see the best growth?

-- What are the major drivers for M&A activity in the biopharma market?

Table of Contents

The future of the biologicals market

Executive Summary 10

Introduction to biopharmaceuticals 10

Developments in technology and clinical applications 11

Market analysis 12

The biopharmaceutical industry 13

Chapter 1 Introduction to biopharmaceuticals 16

Summary 16

Introduction 17

Definition 18

Main product classes 19

Monoclonal antibodies (MAbs) 19

Therapeutic proteins 21

Hemopoietic growth factors 22

Cytokines 23

Blood factors 24

Vaccines 25

Traditional vaccines 25

Novel vaccine technologies 25

Current status: uses and markets 26

Monoclonal antibodies 26

Anti-cancer 27

Anti-TNF 30

Market status of mAbs 31

Therapeutic proteins 33

Insulin 33

Erythropoietin 33

Growth hormone 34

Cytokines 35

Blood factors 37

Market status of therapeutic proteins 37

Vaccines 39

Chapter 2 Developments in technology and clinical applications 42

Summary 42

Introduction 43

Monoclonal antibodies 43

Technology 43

Human antibodies 44

Antibody fragments 44

Conjugated antibodies 45

Antibodies in advanced development 46

Pipeline activity 47

Oncology 47

Abagovomab 47

Anyara 48

Humax EGFr 48

Rencarex 49

Ipilimumab 49

Others 50

Inflammation and immunology 52

Benlysta 52

Epratuzumab 53

Ocrelizumab 53

Reslizumab 54

Others 55

Other indications 55

Bapineuzumab 56

Otelixizumab 57

Pagibaximab 58

Tanezumab 58

Others 58

Therapeutic proteins 59

Technology 59

Multikine 60

Cintredekin Besudotox 61

Rilonacept (IL-1 Trap) 62

Prevascar 63

PRX302 63

Hemopoietic growth factors 64

Recent pipeline activity 65

Replagal 66

Joulferon 68

CYT107 68

Talactoferrin 69

Taspoglutide 70

Vaccines 71

Technology 72

Heterologous prime-boost schemes 72

New adjuvants 73

New vaccines against existing targets 74

Vaccines against new targets 76

HIV vaccines 76

Cancer vaccines 77

Malaria 78

Tuberculosis 79

Vaccines pipeline 80

Menveo 81

Cervarix 81

Ixiaro/Jespect 82

Stimuvax 82

Chapter 3 Market analysis 86

Summary 86

Introduction 87

Market status by product group 88

Monoclonal antibodies 88

Therapeutic proteins 90

Cytokines 91

Anti-hemophilia products 92

Growth hormones 93

Vaccines 93

Production issues 94

Opportunities in emerging markets 94

Adjuvant developments 95

Therapeutic vaccines 95

Influenza 96

Market by geographic region 97

The threat from biosimilars 98

Rationale for biosimilar development 99

Selected biosimilar developments and introductions 100

EPO 100

G-CSF 101

Interferons 101

HGH 101

Monoclonal antibodies 102

Chapter 4 The biopharmaceutical industry 104

Summary 104

Evolution 105

Amgen, Biogen and Genentech 106

Involvement of big pharma 108

Biopharma specialist companies 110

M&A activity 110

Key findings 111

Future M&A trends 113

Chapter 5 Company profiles 116

Introduction 116

Companies marketing/researching Monoclonal Antibodies: 116

Industry leaders 116

Abbott Laboratories 116

Bayer Schering Pharma Ag 117

Biogen Idec Inc. 118

Genzyme Corporation 118

Imclone Systems Inc. 120

UCB S.A. 121

F. Hoffmann-La Roche Ltd 122

Medarex Inc. 123

Other companies involved in MAb research 124

Amgen Inc 124

Apogenix GmbH 125

Bioinvent International AB 126

Celldex Therapeutics Inc 127

Debiopharm Group 128

Genmab A/S 129

Glycotope GmbH 130

ImmunoGen Inc 131

Innate Pharma 132

Pfizer Inc. 133

Seattle Genetics Inc. 134

Tolerx Inc. 135

Trubion Pharmaceuticals Inc. 136

Wilex AG 137

Companies involved in Therapeutic Proteins 138

Industry Leaders 138

CSL Behring 138

Eli Lilly & Co. 139

Ipsen 140

Merck Serono S.A. 140

Novartis AG 141

Novo Nordisk A/S 143

Baxter International Inc 144

Other companies involved in Therapeutic Protein research 144

Agennix AG 144

Akebia Therapeutics, Inc. 145

Biovitrum AB 146

Cytheris SA 147

Dyax Corp 147

ERYtech Pharma 148

Helix BioPharma Corp. 149

Human Genome Sciences Inc. 149

Immutep S.A. 150

H. Lundbeck A/S 152

Octapharma AG 152

Phosphagenics Limited 153

Proteon Therapeutics, Inc. 154

Shire plc 154

Teva Pharmaceutical Industries Ltd 155

ThromboGenics NV 156

ZymoGenetics, Inc. 157

Companies involved in Vaccines 158

Industry Leaders 158

Merck & Co Inc. 158

GlaxoSmithKline plc 159

Sanofi-Aventis 160

Other companies involved in Vaccine Research 161

Advaxis Inc 161

Hawaii Biotech, Inc. 162

ImmunoVaccine Technologies Inc. 163

Intercell AG 164

Soligenix, Inc. 165

Stallergenes 166

Tripep AB 167

Vical Inc 167

Xcellerex, Inc 169

Index 170

List of Figures

Figure 1.1: Global biopharmaceutical market ($bn), 2009 19

Figure 1.2: Diagram of typical antibody structure 20

Figure 1.3: MAb market 2009, market share by use 26

Figure 1.4: Therapeutic proteins market, 2009 market, sales by class, $bn 38

Figure 3.5: Evolution of the biologics market 2009-2015 87

Figure 3.6: Geographic breakdown of the global biopharmaceutical market 98

List of Tables

Table 1.1: Marketed Anti-TNF MAbs 31

Table 1.2: Global market forecast for mAbs, 2009-2015, $bn 32

Table 1.3: mAb market leaders, 2009 32

Table 1.4: Human growth hormone products 35

Table 1.5: Approved cytokines 36

Table 1.6: Blood factors for hemophilia treatment 37

Table 1.7: Global therapeutic proteins market and forecast, $bn 38

Table 1.8: Leading vaccine product sales, 2009; $bn 40

Table 1.9: Global vaccines market and forecast, 2009-2015, $bn 40

Table 2.10: MAbs near to market launch, 2010 46

Table 2.11: Anti-cancer monoclonal antibody products in Phase III trials 47

Table 2.12: Immune system related monoclonal antibody products in Phase III trials 52

Table 2.13: mAb products in clinical development for novel indications 56

Table 2.14: Therapeutic proteins in development 65

Table 2.15: Therapeutic proteins in development (continued) 66

Table 2.16: Vaccines in late stage development 80

Table 3.17: Biopharmaceutical market, estimated value and forecast 2009-2015; $bn 87

Table 3.18: Leading monoclonal antibody products in 2009 89

Table 3.19: Hemopoietic growth factors 90

Table 3.20: Cytokines sales. 2009 91

Table 3.21: Anti-hemophilia products sales, 2009 92

Table 3.22: Growth factor product sales, 2008 93

Table 3.23: Leading vaccine products, sales 2009, $bn 97

Table 3.24: Biologics facing the launch of biosimilars 100

Table 4.25: Company dependence on biopharmaceuticals 109

Table 4.26: Leading specialist biotech companies 110

To order this report:

Biopharmaceutical Industry: The Future of the Biologicals Market: Market overview, innovations and company profiles

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker